Skip to main content
Shannon Maude, MD, Pediatric Hematology & Oncology, Philadelphia, PA, Children's Hospital of Philadelphia

ShannonMaudeMD

Pediatric Hematology & Oncology • Philadelphia, PA

Pediatric Hematologic Oncology

Physician

Join to view full profile

Dr. Maude is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Maude's full profile

Already have an account?

  • Office

    3401 Civic Center Blvd
    Children's Hospital Of Philadelphia - Hem/Onc
    Philadelphia, PA 19104
    Phone+1 215-590-3535
    Fax+1 215-590-3992
  • Is this information wrong?

Education & Training

  • Children's Hospital of Philadelphia
    Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2009 - 2012
  • Children's Hospital of Philadelphia
    Children's Hospital of PhiladelphiaResidency, Pediatrics, 2006 - 2009
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2006

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2006 - 2024
  • American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell  
    Vijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature

Abstracts/Posters

  • Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy
    Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019
    Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
    Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

  • Researchers Use ‘Humanized’ CAR T Cells to Improve Treatment Durability for Patients with ALL
    Researchers Use ‘Humanized’ CAR T Cells to Improve Treatment Durability for Patients with ALLSeptember 8th, 2021
  • Durable Responses with CAR T-cell Retreatment in Young ALL Patients
    Durable Responses with CAR T-cell Retreatment in Young ALL PatientsJune 25th, 2021
  • CAR T-cell Therapy Hailed as Transformative in Pediatric Medicine
    CAR T-cell Therapy Hailed as Transformative in Pediatric MedicineDecember 20th, 2018
  • Join now to see all

Hospital Affiliations

Dr. Shannon Maude, Dr. Shannon Maude, MD, Dr. S Maude